Cheng JD, Chai LX, Zhao ZP, et al. - This retrospective study evaluated 118 patients suffering from advanced non-small cell lung cancer (NSCLC) who progressed following standard regimens to determine if anlotinib is an efficacious and safe treatment option for this group of patients in real world situations, as well as a preliminary analysis of a predictor of effectiveness. The estimated objective response rate and disease control rate were 8.47% and 75.42%, respectively. The median progression-free survival (PFS) and the median overall survival were estimated to be 4.3 months and 10.3 months, respectively. For PFS, ECOG score was identified as an independent factor in Cox regression analysis. Patients with hypertension vs those without hypertension were shown to have better PFS, as indicated in the preliminary analysis of a predictor of effectiveness. Overall, findings demonstrated the effectiveness as well as the safety of anlotinib in the treatment of patients with advanced NSCLC who progressed following standard regimens in real world settings. The likely utility of hypertension as a biomarker for efficacy prediction was suggested.